CROI 2023

Last Updated: August 8, 2024

#PutPeopleFirst – the official social campaign of AIDS 2024

*Conference Programme*
	Conference Programme Sessions	Conference Programme Abstracts
	Conference Programme Pre-Conferences	Conference Programme Exhibition

*Presenters @ AIDS 2024*
	ABT Global at AIDS 2024	AVAC at AIDS2024	EGPAF at AIDS 2024
	HPTN at AIDS 2024	IntraHealth at AIDS 2024	NIH at AIDS 2024
	PEPFAR at AIDS 2024	UNITAID at AIDS 2024	WHO at AIDS 2024

*Updates @ AIDS 2024*
	Day 2 at AIDS 2024: NIH Research Updates, Inequities, U=U, and Doxy PrEP 25th International AIDS Conference; July 22-26, 2024	Day 3 at AIDS 2024: Research Updates, HIV Criminalization Laws, and AI 25th International AIDS Conference; July 22-26, 2024	Day 4 AIDS 2024: Long-Acting Injectables, Bi-Directional Learning, PACHA & More 25th International AIDS Conference; July 22-26, 2024
	Putting People First: IAS Closing Day 25th International AIDS Conference; July 22-26, 2024	MHE Week in Review \| AIDS 2024 Managed Healthcare \| July 28, 2024	Live at #AIDS2024: Highlighting U=U HIV.gov \| AIDS 2024 \| July 22-26, 2024
	U=U University Conversation from AIDS 2024 25th International AIDS Conference; July 22-26, 2024	Takeaways from AIDS 2024 CSIS \| August 7, 2024	AIDS 2024 Photo Gallery

*Highlights @ AIDS 2024*
	An assessment of clinical frailty and early aging among a cohort of people living with HIV in Ontario, Canada 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Comprehensive geriatric assessment for people living with HIV and frailty: a feasibility randomized controlled trial 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Perceptions on frailty and frailty screening of people living with HIV and their healthcare professionals in Ethiopia: a qualitative study 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Frailty and multimorbidity in mid-aged and older adults living with HIV: a cross-sectional study in Zimbabwe 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Polypharmacy Contributes to Frailty & Falls - CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Hypertension management and risk of dementia in people with and without HIV infection 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons... 25th International AIDS Conference \| Courtesy NATAP \| August 1, 2024
	"The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily... 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the... 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide... 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in the international randomised clinical trial: D2EFT 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	What drives Comorbidities in PWH Highlights From Aging Pre-Conference Talks, at AIDS 2024 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Assessing Comorbid Conditions in HIV/AIDS Patients: Insights from the CHAO (Comorbidities of HIV/AIDS Outpatients) Study in Meru County... 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Prevalence and associated factors of chronic kidney disease in young people living with HIV in Uganda 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells 25th International AIDS Conference \| Courtesy NATAP \| July 31, 2024
	ViiV Healthcare Announces Positive New Data For Apretude Use During Pregnancy At AIDS 2024 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	ViiV Healthcare Announces Positive Data Demonstrating 2-Drug Regimen Dovato Is As Effective As 3-Drug Regimen Biktarvy For Maintenance... 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	ViiV Healthcare Premieres Early Data Showing Antiviral Activity Against Integrase Resistance From Its Investigational, Third-Generation Integrase... 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non-AIDS-Related Comorbidities 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Fine Differences Among Five Anal Cancer Screening Strategies in HIV Group 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Preclinical Assessments of a Cabotegravir Prodrug Predicting Human Dosing Durations of >6 Months 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Prevalence of high risk penile human papillomavirus in men who have sex with men (MSM) and transgender women (TGW) 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Pre-Clinical Profiles of HIV-1 Capsid Inhibitors VH4004280 (VH-280) and VH4011499 (VH-499) 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Injection Site Reactions with Subcutaneous Lenacapavir Administration at Alternate Injection Sites 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy 25th International AIDS Conference \| Courtesy NATAP \| July 30, 2024
	Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024
	The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT/Δ32... 25th International AIDS Conference \| Courtesy NATAP \| July 29, 2024

*Highlights @ AIDS 2024*
	Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine... 25th International AIDS Conference \| Courtesy NATAP \| July 28, 2024
	Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi 25th International AIDS Conference \| Courtesy NATAP \| July 28, 2024
	A pilot study assessing changes in cerebral function parameters in persons with insomnia switching integrase inhibitors 25th International AIDS Conference \| Courtesy NATAP \| July 28, 2024
	DoxyPrEP Cuts STI Rate in FSW Without Fueling Other Infections 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	A pilot, randomized controlled trial of doxycycline pre-exposure prophylaxis versus placebo for prevention of bacterial sexually transmitted infections... 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral... 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Bictegravir Plus Lenacapavir Keep Control of HIV in People on Complex Regimens 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Additional Time PostIntegrase Inhibitor to Protease Inhibitor Switch Shows Trend to Weight Loss: DEFINE 48-week Results 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with... 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Failure to achieve undetectable viral load caused by HIV expression from defective proviruses and large reservoir size 25th International AIDS Conference \| Courtesy NATAP \| July 27, 2024
	Randomised placebo-controlled trial of high-dose vitamin D and low-dose calcium supplementation to improve bone density in adolescents with... 25th International AIDS Conference; July 22-26, 2024
	Leaders welcome advances in HIV science while warning of growing threats to progress at 25th International AIDS Conference 25th International AIDS Conference; July 22-26, 2024
	UNAIDS urges leaders to ‘act now’ to overcome the world’s deadliest pandemic at AIDS 2024 UNAIDS \| July 26, 2024
	Doctor behind trial of HIV prevention drug recounts breakthrough moment The Guardian \| July 26, 2024
	Experts Warn of Ongoing Monkeypox Threat Despite Progress in Vaccination and Behavioral Changes \| AIDS 2024 Managed Healthcare \| July 26, 2024
	Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline Gilead \| July 25, 2024
	Twice-Yearly PrEP Gives 'Huge' 100% Protection Medscape \| July 25, 2024
	A seventh case of HIV cure reported at AIDS 2024 WHO \| July 25, 2024
	With PrEP Effort Lagging, Positive Results for Twice-Yearly Lenacapavir May Give a Lift Managed Healthcare \| July 25, 2024
	Long-Acting Injectable Cabotegravir for HIV Prevention Is Safe in Pregnancy HIV.gov \| July 25, 2024
	Research Updates, HIV Criminalization Laws, and AI (VIDEO) NIH \| July 25, 2024
	Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis. 25th International AIDS Conference \| Courtesy NATAP \| July 24, 2024
	Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in... 25th International AIDS Conference \| Courtesy NATAP \| July 24, 2024
	No Confirmed Virological Failures (CVF) for 144 Weeks When Switching 2-/3-/4-Drug ART to DTG/3TC in Heavily Treatment-Experienced PLWHA... 25th International AIDS Conference \| Courtesy NATAP \| July 24, 2024
	Interventions for Improving HIV Care Continuum Outcomes Among LGBTQ+ Youth in the United States: A Narrative Review NIH \| July 24, 2024
	HIV Science Updates from #AIDS202 with Dr. Carl Dieffenbach HIV.gov \| July 24, 2024
	Addressing Structural Barriers and HIV Criminalization HIV.gov \| July 24, 2024
	With new HIV infections rising in a growing number of countries and regions, urgent action is needed to turn the prevention crisis around UNAIDS \| July 24, 2024
	Bridging mind and body: The interconnectedness of HIV and mental health 25th International AIDS Conference; July 22-26, 2024
	HIV Science Updates from #AIDS202 with Dr. Carl Dieffenbach HIV.gov \| July 24, 2024
	NIH Research Updates, Inequities, U=U, and Doxy PrEP NIH \| July 24, 2024
	PrEPVacc HIV vaccine trial shows no reduction in infections News Medical \| July 23, 2024
	Addressing HIV Service Gaps Through Young People \| AIDS 2024 Managed Healthcare \| July 23, 2024
	Pediatric AIDS: Progress But Then a Plateau Managed Healthcare \| July 23, 3034
	Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV Manager Healthcare \| July 23, 2024
	Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral... AIDS 2024, the 25th International AIDS Conference; July 22-26, 2024; Munich, Germany
	Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV Manager Healthcare \| July 23, 2024
	Germany calls for intensified global efforts to combat AIDS epidemic Anadolu Agency \| July 23, 2024
	An Isolated Viral Load Test May Generate False Positive Results for People Using Long-Acting PrEP HIV.gov \| July 23, 2024
	Unfinished business: only urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030 UNICEF \| July 22, 2024
	New UNAIDS report shows AIDS pandemic can be ended by 2030, but only if leaders boost resources and protect human rights now UNAIDS \| July 22, 2024
	WHO releases technical brief on reducing HIV-related stigma and discrimination in healthcare settings WHO \| July 22, 2024
	Breakthrough in HIV cure: Seventh person worldwide appears cured The Jerusalem Post \| July 21, 2024
	Research to watch out for at AIDS 2024 i-base \| July 18, 2024
	Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024 Business Wire \| July 16, 2024
	ViiV Healthcare To Announce Data From Largest Head-To-Head Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug... ViiV Healthcare \| July 15, 2024


14–17 July 2025 The 13th IAS Conference on HIV Science IAS 2025, the 13th IAS Conference on HIV Science, will take place in Kigali, Rwanda, from 14 to 17 July 2025. Pre-meetings will be held on 13 July. An estimated 6,000 participants from around the world will attend IAS 2025. The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational HIV research that move science into policy and practice. Through its open and inclusive programme, the meeting sets the gold standard of HIV science, featuring highly diverse and cutting-edge research.